A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
Solid Tumors Harboring a TP53 Y220C Mutation
DRUG: GenSci128 tablets
Incidence and severity of adverse events (AEs) and dose limiting toxicities (DLTs), Part 1 is a dose escalation study ，to assess the safety and tolerability of GenSci128 in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation, 3 weeks|maximal tolerance dose （MTD）、recommended dose of expansion （RDE）, Part 1 is a dose escalation study ，to determine the maximum tolerated dose (MTD), if any, and recommend dose of expansion (RDE) for GenSci128 in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation, up to 3 months|recommended phase 2 dose （RP2D）, Part 2 is a dose expansion study，Determining Recommended Phase II Dose, up to 3 months
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation